1. Scrip
  2. >>Business
  3. >>Strategy

Say Goodbye To NASH And Hello To MASH

 
• By Joseph Haas

The revised nomenclature of metabolic dysfunction-associated steatohepatitis (MASH), rather than non-alcoholic steatohepatitis (NASH), appears to be taking hold among stakeholders in the liver disease space.

Name change
The biopharma industry gradually is adapting to the name change from NASH to MASH • Source: Shutterstock

The shift in terminology from NASH to MASH seems to be taking hold judging by public statements from companies working in the space, as well as some of the market analysts commenting on developments in metabolic dysfunction-associated steatohepatitis, the disease formerly known as non-alcoholic steatohepatitis.

The nomenclature change is intended to de-stigmatize the disease by eliminating references to alcohol use and fatty liver and also...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

Second Quarter M&A Activity Looks Like More Of The Same, Mostly

 
• By Joseph Haas

The biopharma sector booked nearly the same number of acquisitions in each of the past two quarters, according to Evaluate data, but there are some encouraging signs in Q2.

How Teva Is Expanding Innovation To Fuel ‘Pivot To Growth’

 
• By Jessica Merrill

Teva VP-global R&D and chief medical officer Eric Hughes talked to Scrip about building the company’s innovative pipeline in its growth-acceleration phase.

Will AstraZeneca Reach Summit And Be A PD-1xVEGF Player?

 
• By Kevin Grogan

Rumor mill suggests a $15bn licensing deal for ivonescimab is in the offing.

Novartis’s Cosentyx Suffers Rare Phase III Fail

 
• By Kevin Grogan

Multi-blockbuster falls short in a giant cell arteritis study.

More from Business

Will AstraZeneca Reach Summit And Be A PD-1xVEGF Player?

 
• By Kevin Grogan

Rumor mill suggests a $15bn licensing deal for ivonescimab is in the offing.

Eolo Pharma Advances In Obesity With Thermogenesis Approach

 
• By Aakash Babu

Emerging Company Profile: Early-stage biotech Eolo will seek cash and deals for its novel obesity drug SANA after positive Phase I results for weight loss, lean muscle mass preservation and fat mass reduction.

Novartis’s Cosentyx Suffers Rare Phase III Fail

 
• By Kevin Grogan

Multi-blockbuster falls short in a giant cell arteritis study.